Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590523296> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2590523296 endingPage "692" @default.
- W2590523296 startingPage "692" @default.
- W2590523296 abstract "692 Background: Increasing use of subsequent lines of therapy and crossover in phase III randomized clinical trials (P3 RCTs) has shifted how we perceive the effectiveness of treatments for metastatic colorectal cancer (mCRC). This study aims to characterize the evolution of P3 RCTs in mCRC with respect to clinical trial design and result interpretation. Methods: Abstracts of P3 RCTs of systemic therapy for mCRC conducted between 1980 and 2014 were identified by searching PubMed, Medline, and ASCO abstracts. Data regarding trial design, agent(s) investigated, primary endpoint, secondary endpoint(s), primary endpoint significance and interpretation of the study results (conclusions) were extracted. Results: A total of 422 trials were identified by the search strategy, and 132 eligible trials were included. Over time the sample size of P3 RCTs in mCRC has been increasing and there has been a steady increase in trials studying targeted therapy (see table below for detailed results by decade). A trend towards a smaller percentage of P3 RCTs sponsored by co-operative groups has been observed in recent decades. The most common primary endpoint was overall survival (OS) which was used in 35% of the trials. A decreasing trend in the use of OS was observed since the 1990s. Other common primary endpoints include: progression-free survival (PFS) in 28% and response rate (RR) in 20% of the P3 RCTs. The primary endpoint was met in 45% of the trials. There was discordance between the primary endpoint significance and the authors’ conclusions in 14% of the trials. Conclusions: The design and interpretation of P3 RCTs for mCRC has changed over time from 1980 to present. The use of OS as the primary endpoint is decreasing, while the use of PFS is increasing. [Table: see text]" @default.
- W2590523296 created "2017-03-03" @default.
- W2590523296 creator A5008024031 @default.
- W2590523296 creator A5021374555 @default.
- W2590523296 creator A5023283384 @default.
- W2590523296 creator A5052560259 @default.
- W2590523296 creator A5080776657 @default.
- W2590523296 creator A5087993120 @default.
- W2590523296 date "2015-01-20" @default.
- W2590523296 modified "2023-09-26" @default.
- W2590523296 title "Trends in the design and interpretation of metastatic colorectal cancer phase III clinical trials." @default.
- W2590523296 doi "https://doi.org/10.1200/jco.2015.33.3_suppl.692" @default.
- W2590523296 hasPublicationYear "2015" @default.
- W2590523296 type Work @default.
- W2590523296 sameAs 2590523296 @default.
- W2590523296 citedByCount "0" @default.
- W2590523296 crossrefType "journal-article" @default.
- W2590523296 hasAuthorship W2590523296A5008024031 @default.
- W2590523296 hasAuthorship W2590523296A5021374555 @default.
- W2590523296 hasAuthorship W2590523296A5023283384 @default.
- W2590523296 hasAuthorship W2590523296A5052560259 @default.
- W2590523296 hasAuthorship W2590523296A5080776657 @default.
- W2590523296 hasAuthorship W2590523296A5087993120 @default.
- W2590523296 hasConcept C105795698 @default.
- W2590523296 hasConcept C121608353 @default.
- W2590523296 hasConcept C126322002 @default.
- W2590523296 hasConcept C129848803 @default.
- W2590523296 hasConcept C141341695 @default.
- W2590523296 hasConcept C143998085 @default.
- W2590523296 hasConcept C148482608 @default.
- W2590523296 hasConcept C168563851 @default.
- W2590523296 hasConcept C203092338 @default.
- W2590523296 hasConcept C2780739268 @default.
- W2590523296 hasConcept C3019894029 @default.
- W2590523296 hasConcept C33923547 @default.
- W2590523296 hasConcept C526805850 @default.
- W2590523296 hasConcept C535046627 @default.
- W2590523296 hasConcept C71924100 @default.
- W2590523296 hasConceptScore W2590523296C105795698 @default.
- W2590523296 hasConceptScore W2590523296C121608353 @default.
- W2590523296 hasConceptScore W2590523296C126322002 @default.
- W2590523296 hasConceptScore W2590523296C129848803 @default.
- W2590523296 hasConceptScore W2590523296C141341695 @default.
- W2590523296 hasConceptScore W2590523296C143998085 @default.
- W2590523296 hasConceptScore W2590523296C148482608 @default.
- W2590523296 hasConceptScore W2590523296C168563851 @default.
- W2590523296 hasConceptScore W2590523296C203092338 @default.
- W2590523296 hasConceptScore W2590523296C2780739268 @default.
- W2590523296 hasConceptScore W2590523296C3019894029 @default.
- W2590523296 hasConceptScore W2590523296C33923547 @default.
- W2590523296 hasConceptScore W2590523296C526805850 @default.
- W2590523296 hasConceptScore W2590523296C535046627 @default.
- W2590523296 hasConceptScore W2590523296C71924100 @default.
- W2590523296 hasIssue "3_suppl" @default.
- W2590523296 hasLocation W25905232961 @default.
- W2590523296 hasOpenAccess W2590523296 @default.
- W2590523296 hasPrimaryLocation W25905232961 @default.
- W2590523296 hasRelatedWork W2009370781 @default.
- W2590523296 hasRelatedWork W2028889234 @default.
- W2590523296 hasRelatedWork W2074146123 @default.
- W2590523296 hasRelatedWork W2130626169 @default.
- W2590523296 hasRelatedWork W2339228323 @default.
- W2590523296 hasRelatedWork W4282918911 @default.
- W2590523296 hasRelatedWork W4318145936 @default.
- W2590523296 hasRelatedWork W4361907936 @default.
- W2590523296 hasRelatedWork W4362394812 @default.
- W2590523296 hasRelatedWork W4362394888 @default.
- W2590523296 hasVolume "33" @default.
- W2590523296 isParatext "false" @default.
- W2590523296 isRetracted "false" @default.
- W2590523296 magId "2590523296" @default.
- W2590523296 workType "article" @default.